• Recruiting

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL

Updated: May 24

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EZM0414

A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma


This is a first-in-human (FIH), 2-part, open-label, multi-center, Phase 1/1b safety, tolerability, pharmacokinetics (PK), and efficacy study of oral SETD2 inhibitor, EZM0414, in subjects with relapsed/refractory (R/R) Multiple Myeloma (MM) and R/R Diffuse Large B-Cell Lymphoma (DLBCL).


Sponsor

Epizyme, Inc


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT05121103


Official Title: A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma


First Posted : November 16, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: EZM0414

 

EZM 0414


SETD2 Inhibitor EZM0414 (Code C185420)

EZM 0414

EZM-0414

EZM0414

SETD2 Inhibitor EZM0414

 

Locations

United States, Maryland

United States, Massachusetts

United States, New Jersey

United States, New York

United States, Texas

United States, Virginia





Posts Archive